Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Prempro Osteoporosis Use In Older Women May Be Limited To Second-Line

Executive Summary

Wyeth is considering revising Prempro's indication to more clearly define the hormone therapy as second-line osteoporosis prevention for older women
Advertisement

Related Content

Hormone Therapy Osteoporosis Approval Hurdle Unchanged By WHI, FDA Says
Hormone Therapy Osteoporosis Approval Hurdle Unchanged By WHI, FDA Says
Hormone Therapy Osteoporosis Approval Hurdle Unchanged By WHI, FDA Says
Wyeth Prempro Gets Dementia Warning; FDA Considering HRT Class Labeling
Wyeth Prempro Gets Dementia Warning; FDA Considering HRT Class Labeling
Hormone Therapy Class Labeling Uses Wyeth Template; Appeals Due By March
Advertisement
UsernamePublicRestriction

Register

PS042627

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel